GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Steminent Biotherapeutics Inc (ROCO:7729) » Definitions » ROA %

Steminent Biotherapeutics (ROCO:7729) ROA % : -30.42% (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Steminent Biotherapeutics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Steminent Biotherapeutics's annualized Net Income for the quarter that ended in Jun. 2024 was NT$-167.21 Mil. Steminent Biotherapeutics's average Total Assets over the quarter that ended in Jun. 2024 was NT$549.61 Mil. Therefore, Steminent Biotherapeutics's annualized ROA % for the quarter that ended in Jun. 2024 was -30.42%.

The historical rank and industry rank for Steminent Biotherapeutics's ROA % or its related term are showing as below:

ROCO:7729' s ROA % Range Over the Past 10 Years
Min: -65.42   Med: -44.15   Max: -31.16
Current: -32.57

During the past 4 years, Steminent Biotherapeutics's highest ROA % was -31.16%. The lowest was -65.42%. And the median was -44.15%.

ROCO:7729's ROA % is ranked better than
52.07% of 1498 companies
in the Biotechnology industry
Industry Median: -34.185 vs ROCO:7729: -32.57

Steminent Biotherapeutics ROA % Historical Data

The historical data trend for Steminent Biotherapeutics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Steminent Biotherapeutics ROA % Chart

Steminent Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROA %
-55.11 -65.42 -33.18 -31.16

Steminent Biotherapeutics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROA % Get a 7-Day Free Trial -22.18 -46.24 -23.81 -32.66 -30.42

Competitive Comparison of Steminent Biotherapeutics's ROA %

For the Biotechnology subindustry, Steminent Biotherapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Steminent Biotherapeutics's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Steminent Biotherapeutics's ROA % distribution charts can be found below:

* The bar in red indicates where Steminent Biotherapeutics's ROA % falls into.


;
;

Steminent Biotherapeutics ROA % Calculation

Steminent Biotherapeutics's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-129.229/( (235.65+593.876)/ 2 )
=-129.229/414.763
=-31.16 %

Steminent Biotherapeutics's annualized ROA % for the quarter that ended in Jun. 2024 is calculated as:

ROA %=Net Income (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=-167.206/( (593.876+505.349)/ 2 )
=-167.206/549.6125
=-30.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Jun. 2024) net income data. ROA % is displayed in the 30-year financial page.


Steminent Biotherapeutics  (ROCO:7729) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jun. 2024 )
=Net Income/Total Assets
=-167.206/549.6125
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-167.206 / 0)*(0 / 549.6125)
=Net Margin %*Asset Turnover
=N/A %*0
=-30.42 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Steminent Biotherapeutics ROA % Related Terms

Thank you for viewing the detailed overview of Steminent Biotherapeutics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Steminent Biotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
No.16,Wenhu Street, Neihu District, Taipei, TWN, 11445
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.

Steminent Biotherapeutics Headlines

No Headlines